Benzquercin is a member of flavones. Experiments on mice have shown that compound decreased morphological disorders of the connective tissue of lathyritic mice and the vascular permeability was close to normal controls.

IPSAPIRONE, an azapirone derivative structurally unrelated to the benzodiazepines, is a selective 5-HT1A serotonin receptor agonist. It has antidepressant and anxiolytic effects. IPSAPIRONE was studied in several clinical trials for depression and generalized anxiety disorder.

Ecomustine, or CY233 (NSC-609224), is a water-soluble nitrosoureido derivative of deoxysugar exerting antineoplastic activity. It acts as an alkylating agent. It demonstrated effectivity in the treatment of tumors in animal models.

Prampine is the anticholinergic agent. It was used for the treatment of peptic ulcers. According to the virtual screening, prampine has a good binding affinity with acetylcholinesterase.

Aptocaine (Pirothesin, Pharmaceutical Manufacturing Company) is a new local anaesthetic agent, the first of note to be synthesized in Britain. It is related toprilocaine; like prilocaine, it has a low sub-cutaneous toxicity, but preliminary studies suggest that, unlike prilocaine, it does not induce methaemoglobinaemia. It has been found to produce satisfactory analgesia, of longer duration than lignocaine, by several routes, at a concentration of 3% in animals.

Bamaquimast was developed by Pierre Fabre as an inhibitor of the proton pump with anti-inflammatory and anti-asthmatic effects. This drug participated in phase II clinical trials for the treatment of patients with asthma. However, these studies were discontinued.

Azipramine, an antidepressant, that never been marketed.

Balaglitazone is a second generation peroxisome proliferator-activated receptor (PPAR) gamma agonist with only partial agonistic properties. It passed phase III clinical trial for the treatment of type 2 diabetes. However, Dr. Reddy's Laboratories decided to terminate further clinical development of balaglitazone.

Antafenite is an anthelminthic drug.

Rodorubicin (Cytorhodin S, HLB 817) is a synthetic tetraglycosidic anthracycline antibiotic with antineoplastic activity. Rodorubicin is thought to intercalate DNA and cause cell death. Compared to standard anthracyclines, this compound has an atypical spectrum of activity and toxicity. Rodorubucin was the first drug that was being developed clinically despite its inactivity in animal transplantation tumor systems (it was detected in a human tumor-based screening system). Delayed nephrotoxicity is the dose-limiting factor for this drug, namely proteinuria and clearance reduction. Because of the severe side effects, rodobubicin was never marketed.